Clinical trials: Geriatric Individuals
Herpes Zoster (HZ)
A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals
The purpose of this clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy individuals aged 40 years and above.
- Trial name
- NCT06932523
- Testing
- Recombinant herpes zoster vaccine with low-dose adjuvant, Recombinant herpes zoster vaccine with high-dose adjuvant, Low-dose adjuvant
- Where
- China
- Volunteers
- 645 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Alzheimer's Disease
Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals
This study will evaluate the performance characteristics of a novel [18F] amyloid detection ligand (18F]-AV-45) with respect to its ability to distinguish patients with clinically-diagnosed probable Alzheimer's disease from…
- Trial name
- NCT00855868
- Testing
- florbetapir F 18, [11C]-PIB
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Tetanus, Tetanus Vaccine
Phase I/III Clinical Trial of Adsorbed Tetanus Vaccine
The study aimed to evaluate the safety and immunogenicity of an adsorbed tetanus vaccine in healthy individuals between 18 and 43 years of age.
- Trial name
- NCT07740733
- Testing
- Tetanus Toxoid (Adsorbed)
- Where
- China
- Volunteers
- 1,240 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Streptococcus Pneumoniae Infection
Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)
This clinical trial consists of Phase I and Phase II. The objective is to evaluate the safety and immunogenicity of the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) in individuals aged 2 months…
- Trial name
- NCT07600983
- Testing
- 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M), PCV24 vaccine (dose H), PCV24 vaccine (dose M)
- Where
- 2 sites in China
- Volunteers
- 854 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Colorectal Cancer
An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now
The primary objective is to confirm the specificity of a multi-target stool DNA test (mt-sDNA), Cologuard, in an average risk population, ages 45-49.
- Trial name
- NCT03728348
- Testing
- mt-sDNA screening test, Colonoscopy
- Where
- 39 sites in United States
- Volunteers
- 983 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
COVID-19
Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases
The purpose of the study is to evaluate the safety and immunogenicity of the investigational CpG 1018/Alum-adjuvanted recombinant SARS-CoV-2 trimeric spike (S)-protein subunit vaccine (SCB-2019) in adult participants with stable…
- Trial name
- COVID-19 (NCT05012787)
- Testing
- CpG 1018/Alum-adjuvanted SCB-2019 vaccine, Havrix
- Where
- 4 sites in Ukraine
- Volunteers
- 1 people
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Atrial Fibrillation, Atrial Flutter
A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of Stroke
The purpose of this study is to determine if an AF detection intervention in men and women at least 70 years of age with undiagnosed atrial fibrillation (AF) or atrial flutter (AFL) reduces the person-years incidence rate of…
- Trial name
- GUARD-AF (NCT04126486)
- Testing
- Zio®XT Monitor
- Where
- 176 sites in United States
- Volunteers
- 11,931 people
- Sponsor
- Bristol-Myers Squibb
SARS-CoV-2
Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals
The objective of the study is to demonstrate safety and immunogenicity of COVID-19 preventive DNA vaccine in elderly individuals.
- Trial name
- NCT04915989
- Testing
- GX-19N
- Where
- 2 sites in South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.
No Condition, Healthy Individuals, No Conditions, Aged 20-64
Evaluating the Hemodynamic Performance of the VenAir Sequential Compression System
The goal of this clinical trial is to learn an Intermittent Pneumatic Compression Device (IPCD), VenAir, effectiveness in healthy adults. The main questions this research aims to answer are: 1.
- Trial name
- NCT07287007
- Testing
- VenAir, SCD700
- Where
- Taiwan
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Wellell Inc. Taiwan
Seasonal Influenza
Immunogenicity and Safety Study of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
The purpose of this study is to evaluate the safety and immunogenicity of Influenza vaccine (Split virion), Inactivated, Quadrivalent developed by Sinovac Biotech Co., Ltd.
- Trial name
- NCT05431725
- Testing
- Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, Control Quadrivalent influenza virus vaccine
- Where
- 11 sites in Chile, Philippines
- Volunteers
- 2,202 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Mild Cognitive Impairment, Cognitive Decline
Effects of Walkasins on Gait Speed of Individuals With Mild Cognitive Impairments
The primary aim of this pilot study is to investigate the effect of Walkasins, a wearable lower-limb sensory prosthesis, on the gait speed and balance function of participants with mild cognitive impairment as measured by the…
- Conditions
- Mild Cognitive Impairment, Cognitive Decline, Gait Disorders in Old Age
- Trial name
- NCT05723822
- Testing
- Walkasins
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- RxFunction Inc.
Colo-rectal Cancer
Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC.
The primary objective of this sub-study, 2018-10B, is to collect blood specimens to assess new biomarkers for the detection of Colorectal Cancer (CRC).
- Trial name
- NCT03741166
- Testing
- Blood Sample Collection
- Where
- 37 sites in United States
- Volunteers
- 871 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Pneumococcal Diseases
A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60
This Phase I, randomized, double-blind, parallel-controlled study is to be conducted in healthy adults aged 60 and above. Participants will be randomly assigned in a 1:1 ratio to receive either 26-valent Pneumococcal Conjugate…
- Trial name
- NCT06970756
- Testing
- 26-valent Pneumococcal Conjugate Vaccine, 13-valent Pneumococcal Conjugate Vaccine
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Down Syndrome
Non-drug Study to Assess the Suitability of Assessment Scales in Japanese Individuals With Down Syndrome Aged 6-30
To evaluate the suitability (i.e. number of tests completed and number of participants completing the tests, variance estimate of baseline and of the change from baseline values) of neurocognitive tests and functioning scales in…
- Trial name
- NCT02431117
- Where
- 7 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Chugai Pharmaceutical
Rabies (Healthy Volunteers)
Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried
To evaluate the immunogenicity and safety of different post-exposure prophylaxis (PEP) schedules of Sinovac rabies vaccine, in comparison with a marked rabies vaccinein china, in subjects aged 10-60 years old.
- Trial name
- NCT07357545
- Testing
- Sinovac rabies vaccine, Marketed rabies vaccine
- Where
- 2 sites in China
- Volunteers
- 2,040 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
COVID-19
Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China
The purpose of this clinical study, CLO-SCB-2019-010, is to assess the immunogenicity, reactogenicity and safety of the SCB-2019 vaccine in Chinese participants, and to show the comparability of the immune response versus…
- Trial name
- NCT04954131
- Testing
- Candidate Vaccine, SCB-2019
- Where
- 2 sites in China
- Volunteers
- 766 people, healthy volunteers welcome
- Sponsor
- Zhejiang Clover Biopharmaceuticals, Inc.
Respiratory Syncytial Virus Infection
SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER
This post-marketing study is a multicenter cohort study in individuals aged 60 years or older vaccinated with Abrysvo (RSV vaccine）designed to confirm the safety in individuals aged 60 years or older under actual clinical…
- Trial name
- NCT06546800
- Testing
- RSVpreF vaccine
- Where
- Japan
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Pfizer